Coxsackievirus Infections Treatment Market Snapshot (2023 to 2033)
The global coxsackievirus infections treatment market is currently valued at US$ 5.5 Billion in 2023 and is anticipated to expand at a CAGR of 8.2%. Owing to the technological advances in healthcare the market is likely to propel to US$ 12.1 Billion by 2033.
An increase in demand for improved healthcare infrastructure and an increasing incidence rate is likelytodrive the growth of the coxsackievirus infections treatment market in the forecast period.
Report Attribute
Details
Expected Market Value (2023)
US$ 5.5 Billion
Projected Forecast Value (2033)
US$ 12.1 Billion
Global Growth Rate (2023 to 2033)
8.2% CAGR
Coxsackieviruses are non-enveloped viruses belonging to the picornaviridae family and enterovirus genus that possess linear single-stranded RNA as their genetic material. Based on their pathogenicity tested on mice, these are categorized into group A and group B viruses.
Group A viruses are known to cause skin and mucous membrane infections, leading to disorders such as herpangina, hand-foot-and-mouth (HFM) disease, and acute hemorrhagic conjunctivitis (AHC).
Group B viruses infect the pancreas, liver, and heart, leading to various conditions such as pericarditis, hepatitis, myocarditis, and pleurodynia. According to Centers for Disease Control and Prevention (CDC) estimates, coxsackievirus infections accounted for around 25% of the neonatal enterovirus infections reported from 1983 to 2003. People from all age groups get infected by coxsackievirus; however, children are more susceptible to the infection. Fetuses or newborns are at a high risk of infection if their mother gets infected during pregnancy. These viruses are found in the feces, fluid in blisters, nasal secretions, and saliva of an infected patients.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Which are Some Prominent Drivers of Coxsackievirus Infections Treatment Market?
Growing Incidences of Infections Cause by Coxsackievirus to Drive the Market Growth
Major factors driving the global coxsackievirus diagnostics market are an increase in the incidence of coxsackievirus infections, the surge in awareness among the people, and rigorous government initiatives to reduce the incidence of these infections.
Also, the increasing awareness regarding hand, foot, and mouth disease treatment among people, the availability of cost-effective drugs in the market, and the high prevalence of viral infection causing HFMD in children across the globe is expected to be the key factor driving the growth of coxsackievirus infections treatment market.
Increasing investments in research and development activities to drive the market growth
The global coxsackievirus infections treatment market is anticipated to observe impressive growth during the forecast period, 2023 to 2033. Extensive research and development are propelling the growth of the market, globally.
The other factors supporting the market’s growth are, the increasing government investments in research & development activities, the growing footprint of pharmaceutical manufacturers, developed healthcare infrastructure, rising awareness among the masses, and technological advancements.
Also, ease in FDA approvals for hand, foot, and mouth disease (HFMD) drugs in the clinical trial phase is further projected to drive the growth of the coxsackievirus infections treatment market. Owing to the large patient pool due to HFMD, the demand for coxsackievirus infections treatment is upsurging.
Which factors are limiting the growth of Coxsackievirus infections treatment market?
Lack of Awareness Regarding Coxsackievirus to Restrain the Market Growth
One of the major factors hindering the growth of the coxsackievirus infections treatment market over the analysis period includes the lack of awareness regarding the infection. The high cost of therapeutics is another factor that is expected to impede the market growth.
Lack of resources and accessibility in remote areas is one of the key factors likely to hamper the growth of the coxsackievirus infections treatment market. Moreover, the development of more sensitive, efficient, and yet simple rapid diagnostic systems that can be applied to direct and indirect diagnosis remains a challenge in the coxsackievirus infections treatment market.
Find your sweet spots for generating winning opportunities in this market.
Country-Wise Insights
What Makes USA an Attractive Market for Coxsackievirus Infections Treatment?
Advancement in Healthcare to Boost the Market Growth in Region
The market in the North American region is anticipated to observe vibrant growth during the forecast period 2023 to 2033. This can be attributed to the growing developments in the healthcare sector as a result of rising research and development activities in this industry. The region is expected to hold the highest CAGR of 8.0% during the forecast period.
North America led the market in terms of revenue due to the presence of several leading players in the region and various strategic initiatives undertaken by them. Moreover, various government initiatives to promote the diagnosis of various infectious diseases are likely to offer lucrative growth opportunities during the coming years.
For instance, in February 2012, CDC received reports of 63 persons with signs and symptoms of HFMD or with fever and atypical rash in Alabama (38 cases), California (seven), Connecticut (one), and Nevada (17). Coxsackievirus A6 (CVA6) was detected in 25 (74%) of those 34 patients by reverse transcriptase–polymerase chain reaction and partial sequencing of the VP1 gene at the CDC or at the California Department of Public Health.
What makes the Asia Pacific the Most Lucrative Market for Coxsackievirus Infections Treatment Market?
Increasing Prevalence of HFMD in The Region to Boost the Market Growth
The Asia Pacific's coxsackievirus infection treatment market is expected to rise at a CAGR of 7.9% from 2023 to 2033. Asia Pacific dominates the coxsackievirus infection treatment market owing to the high geriatric population and increasing disease burden in economies such as India, China, and South Korea.
Asia Pacific is projected to hold the largest shares in the global coxsackievirus infection treatment market primarily due to the growing prevalence of HFMD in children in the Asia Pacific region coupled with Asia Pacific being the most vulnerable area for a number of outbreaks of EV71 HFMD.
The growing healthcare industry and an aging population consequently would lead to an increased patient population in these countries. India, China, and Brazil are expected to be rapidly growing markets, owing to an increase in investments by governments in order to enhance healthcare facilities.
Country-wise Forecast CAGRs for the Coxsackievirus Infections Treatment Market
United Kingdom
8.0%
India
7.9%
South Korea
7.5%
China
7.6%
United States of America
8.1%
Category wise Insights
Based on Drug Type, Which Is the Most Prominent Segment in Coxsackievirus Infections Treatment Market?
Acetaminophen Segment to Generate Significantly High Revenue
On the basis of drug type coxsackievirus infection treatment market is classified into acetaminophen, paracetamol, and ibuprofen. Among these acetaminophen registers the highest demand in the coxsackievirus infections treatment market owing to the fewer side effects registered with the usage of this drug as compared to others. coxsackievirus infections treatment was found major used in the management of blisters in the mouth and rashes on hands and feet.
The rising prevalence of viral infections in children below age 10 and the growing economic burden caused by HFMD is one of the major factors driving the demand for coxsackievirus infections treatment drugs for the early management of viral infection in children, thereby fueling the market growth over the globe. The Acetaminophen segment held a dominant market share in the year 2023 and is estimated to grow with the fastest CAGR rate of 8.0% over the forecast period 2022 to 2023.
By Distribution Channel, which segment generates high revenue in the Coxsackievirus Infections Treatment market?
Hospital Pharmacy Segment Remains Dominant Among Other Types
The hospital pharmacy segment dominated the global market in 2023 with a revenue share of over 55.0%. The growth of the segment is attributed to the increasing prevalence of coxsackievirus infections and hospitalization for treatment.
Hospital pharmacies preserve the stock of products related to coxsackievirus infections for out-patients as well as in-patients. The segment will be driven further by growing consumer awareness and increased investments in healthcare infrastructure in developing and underdeveloped countries.
The online pharmacies segment is expected to be the fastest-growing distribution channel segment. This growth can be attributed to user-friendly interfaces and convenience offered by these pharmacies, in terms of access, prices, and delivery. In addition, they have several discounts on purchases of a certain amount or offer bundle pricing for many products.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
How do New Entrants Contribute to the Coxsackievirus Infections Treatment Market?
Start-up Scenario
With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the coxsackievirus infections treatment market.
Some of the start-ups in the coxsackievirus infectionstreatment market include-
Provention Bio is a clinical-stage biopharmaceutical company engaged in the sourcing, development, and commercialization of novel therapeutics to intercept and prevent immune-mediated diseases. Its products help in the treatment of chronic autoimmune and inflammatory diseases, such as type 1 diabetes (T1D), Crohn’s disease, ulcerative colitis, and proviral infections. The company's pipeline includes clinical assets licensed from Janssen (2 inflammatory bowel disease candidates, a small-molecule CSF-1R inhibitor JNJ-40346527 for Crohn's disease, and JNJ-42915925, an anti-TLR3 antibody,) and Vactech (Enterovirus vaccine platform to pre-empt type 1 diabetes by targeting Coxsackievirus B infection).
SingVax is focused on the development of prophylactic vaccines for infectious diseases. The company’s product candidates include the Enterovirus 71 vaccine for the prevention of hand, foot, and mouth disease in children; the Japanese Encephalitis (JE) vaccine for the prevention of JE virus infection; and the chikungunya virus vaccine. As of Oct 2009, SingVax was acquired by Inviragen.
Competitive Landscape
Some of the key players present in the global coxsackievirus infections treatment markets are Adimmune Corp., CJ HealthCare Corp., Takeda Pharmaceutical Co Ltd., Shanghai Zerun Biotechnology Co Ltd., Chongqing Zhifei Biological Products Co Ltd., Johnson & Johnson Consumer Inc., GlaxoSmithKline plc., Emergex Vaccines Holdings Ltd, CJ HealthCare Corp., Thermo Fisher Scientific Inc., and others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, applications, and industries.
In January 2023, Thermo Fisher Scientific Inc. announced that it has completed its acquisition of The Binding Site Group a global leader in specialty diagnostics, from a shareholder group led by European private equity firm Nordic Capital.
In October 2022, Emergex Vaccines Holding Limited a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, announces that it has acquired the assets of Zosano Pharma Corporation.
In December 2022, Johnson & Johnson, the world’s largest, most diversified healthcare products company, announced it has completed its acquisition of Abiomed, Inc. Abiomed is now part of Johnson & Johnson and will operate as a standalone business within Johnson & Johnson’s MedTech segment.
Key Segments Covered in the Coxsackievirus Infections Treatment Market Industry Survey
Coxsackievirus Infections Treatment Market by Drug Type:
Acetaminophen
Ibuprofen
Anti-inflammatory
Nucleoside Analogue Antivirals
Others
Coxsackievirus Infections Treatment Market by Route of Administration:
Topical
Oral
Intravenous
Coxsackievirus Infections Treatment Market by Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Coxsackievirus Infections Treatment Market by Region:
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa
Frequently Asked Questions
What Big is the Market for Coxsackievirus Infections Treatment Services?
In 2023, the overall market is estimated to generate a revenue of nearly US$ 5.5 billion.
What is the Best Treatment for Coxsackievirus Infections Worldwide?
The automotive waste segment accounts for over 50% of the global market demand.
What is the Growth of Coxsackievirus Infections Treatment Market in India?
The region is expected to grow at 7.9% CAGR through 2033.
What is the Overview of the United States Coxsackievirus Infections Treatment Market?
The regional market could witness 8.1% CAGR through 2033.
Who will be the Leading Market Players for Waste Recycling Services?
Adimmune, CJ Healthcare, and Takeda are known to be the leading market players.
Table of Content
1. Executive Summary | Coxsackievirus Infections Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033
5.3.1. Acetaminophen
5.3.2. Ibuprofen
5.3.3. Anti-inflammatory
5.3.4. Nucleoside Analogue Antivirals
5.3.5. Others
5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033
6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
6.3.1. Topical
6.3.2. Oral
6.3.3. Intravenous
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. Middle East & Africa (MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Drug Type
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Type
9.3.3. By Route of Administration
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Type
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Type
10.3.3. By Route of Administration
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. UK
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Drug Type
11.2.3. By Route of Administration
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Type
11.3.3. By Route of Administration
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. South Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Drug Type
12.2.3. By Route of Administration
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Type
12.3.3. By Route of Administration
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. East Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Drug Type
13.2.3. By Route of Administration
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Type
13.3.3. By Route of Administration
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Oceania Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Drug Type
14.2.3. By Route of Administration
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Type
14.3.3. By Route of Administration
14.3.4. By Distribution Channel
14.4. Key Takeaways
15. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Drug Type
15.2.3. By Route of Administration
15.2.4. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Type
15.3.3. By Route of Administration
15.3.4. By Distribution Channel
15.4. Key Takeaways
16. Key Countries Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Drug Type
16.1.2.2. By Route of Administration
16.1.2.3. By Distribution Channel
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Drug Type
16.2.2.2. By Route of Administration
16.2.2.3. By Distribution Channel
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Drug Type
16.3.2.2. By Route of Administration
16.3.2.3. By Distribution Channel
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Drug Type
16.4.2.2. By Route of Administration
16.4.2.3. By Distribution Channel
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Drug Type
16.5.2.2. By Route of Administration
16.5.2.3. By Distribution Channel
16.6. UK
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Drug Type
16.6.2.2. By Route of Administration
16.6.2.3. By Distribution Channel
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Drug Type
16.7.2.2. By Route of Administration
16.7.2.3. By Distribution Channel
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Drug Type
16.8.2.2. By Route of Administration
16.8.2.3. By Distribution Channel
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Drug Type
16.9.2.2. By Route of Administration
16.9.2.3. By Distribution Channel
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Drug Type
16.10.2.2. By Route of Administration
16.10.2.3. By Distribution Channel
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Drug Type
16.11.2.2. By Route of Administration
16.11.2.3. By Distribution Channel
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Drug Type
16.12.2.2. By Route of Administration
16.12.2.3. By Distribution Channel
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Drug Type
16.13.2.2. By Route of Administration
16.13.2.3. By Distribution Channel
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Drug Type
16.14.2.2. By Route of Administration
16.14.2.3. By Distribution Channel
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Drug Type
16.15.2.2. By Route of Administration
16.15.2.3. By Distribution Channel
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Drug Type
16.16.2.2. By Route of Administration
16.16.2.3. By Distribution Channel
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Drug Type
16.17.2.2. By Route of Administration
16.17.2.3. By Distribution Channel
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Drug Type
16.18.2.2. By Route of Administration
16.18.2.3. By Distribution Channel
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Drug Type
16.19.2.2. By Route of Administration
16.19.2.3. By Distribution Channel
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Drug Type
16.20.2.2. By Route of Administration
16.20.2.3. By Distribution Channel
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Drug Type
16.21.2.2. By Route of Administration
16.21.2.3. By Distribution Channel
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Drug Type
17.3.3. By Route of Administration
17.3.4. By Distribution Channel
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Adimmune Corp.
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. CJ HealthCare Corp.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Takeda Pharmaceutical Co Ltd.
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Shanghai Zerun Biotechnology Co Ltd.
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Chongqing Zhifei Biological Products Co Ltd.
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Johnson & Johnson Consumer Inc.
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. GlaxoSmithKline plc.
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Emergex Vaccines Holdings Ltd
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. CJ HealthCare Corp.
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Thermo Fisher Scientific Inc.
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 3: Global Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 4: Global Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 5: North America Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 7: North America Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 8: North America Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 9: Latin America Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 11: Latin America Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 12: Latin America Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 13: Europe Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Europe Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 15: Europe Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 16: Europe Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 17: South Asia Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: South Asia Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 19: South Asia Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 20: South Asia Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 21: East Asia Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: East Asia Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 23: East Asia Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 24: East Asia Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 25: Oceania Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: Oceania Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 27: Oceania Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 28: Oceania Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 29: MEA Value (US$ Million) Forecast by Country, 2018 to 2033
Table 30: MEA Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 31: MEA Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 32: MEA Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Value (US$ Million) by Drug Type, 2023 to 2033
Figure 2: Global Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 3: Global Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 4: Global Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 9: Global Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 10: Global Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 11: Global Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 12: Global Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 13: Global Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 14: Global Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 15: Global Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 16: Global Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 17: Global Attractiveness by Drug Type, 2023 to 2033
Figure 18: Global Attractiveness by Route of Administration, 2023 to 2033
Figure 19: Global Attractiveness by Distribution Channel, 2023 to 2033
Figure 20: Global Attractiveness by Region, 2023 to 2033
Figure 21: North America Value (US$ Million) by Drug Type, 2023 to 2033
Figure 22: North America Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 23: North America Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 24: North America Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 29: North America Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 30: North America Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 31: North America Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 32: North America Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 33: North America Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 34: North America Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 35: North America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 36: North America Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 37: North America Attractiveness by Drug Type, 2023 to 2033
Figure 38: North America Attractiveness by Route of Administration, 2023 to 2033
Figure 39: North America Attractiveness by Distribution Channel, 2023 to 2033
Figure 40: North America Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Value (US$ Million) by Drug Type, 2023 to 2033
Figure 42: Latin America Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 43: Latin America Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 44: Latin America Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 49: Latin America Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 50: Latin America Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 51: Latin America Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 52: Latin America Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 53: Latin America Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 54: Latin America Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 55: Latin America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 56: Latin America Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 57: Latin America Attractiveness by Drug Type, 2023 to 2033
Figure 58: Latin America Attractiveness by Route of Administration, 2023 to 2033
Figure 59: Latin America Attractiveness by Distribution Channel, 2023 to 2033
Figure 60: Latin America Attractiveness by Country, 2023 to 2033
Figure 61: Europe Value (US$ Million) by Drug Type, 2023 to 2033
Figure 62: Europe Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 63: Europe Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 64: Europe Value (US$ Million) by Country, 2023 to 2033
Figure 65: Europe Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Europe Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 69: Europe Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 70: Europe Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 71: Europe Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 72: Europe Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 73: Europe Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 74: Europe Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 75: Europe Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 76: Europe Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 77: Europe Attractiveness by Drug Type, 2023 to 2033
Figure 78: Europe Attractiveness by Route of Administration, 2023 to 2033
Figure 79: Europe Attractiveness by Distribution Channel, 2023 to 2033
Figure 80: Europe Attractiveness by Country, 2023 to 2033
Figure 81: South Asia Value (US$ Million) by Drug Type, 2023 to 2033
Figure 82: South Asia Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 83: South Asia Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 84: South Asia Value (US$ Million) by Country, 2023 to 2033
Figure 85: South Asia Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: South Asia Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: South Asia Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: South Asia Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 89: South Asia Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 90: South Asia Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 91: South Asia Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 92: South Asia Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 93: South Asia Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 94: South Asia Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 95: South Asia Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 96: South Asia Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 97: South Asia Attractiveness by Drug Type, 2023 to 2033
Figure 98: South Asia Attractiveness by Route of Administration, 2023 to 2033
Figure 99: South Asia Attractiveness by Distribution Channel, 2023 to 2033
Figure 100: South Asia Attractiveness by Country, 2023 to 2033
Figure 101: East Asia Value (US$ Million) by Drug Type, 2023 to 2033
Figure 102: East Asia Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 103: East Asia Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 104: East Asia Value (US$ Million) by Country, 2023 to 2033
Figure 105: East Asia Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: East Asia Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: East Asia Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: East Asia Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 109: East Asia Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 110: East Asia Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 111: East Asia Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 112: East Asia Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 113: East Asia Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 114: East Asia Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 115: East Asia Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 116: East Asia Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 117: East Asia Attractiveness by Drug Type, 2023 to 2033
Figure 118: East Asia Attractiveness by Route of Administration, 2023 to 2033
Figure 119: East Asia Attractiveness by Distribution Channel, 2023 to 2033
Figure 120: East Asia Attractiveness by Country, 2023 to 2033
Figure 121: Oceania Value (US$ Million) by Drug Type, 2023 to 2033
Figure 122: Oceania Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 123: Oceania Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 124: Oceania Value (US$ Million) by Country, 2023 to 2033
Figure 125: Oceania Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: Oceania Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: Oceania Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: Oceania Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 129: Oceania Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 130: Oceania Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 131: Oceania Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 132: Oceania Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 133: Oceania Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 134: Oceania Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 135: Oceania Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 136: Oceania Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 137: Oceania Attractiveness by Drug Type, 2023 to 2033
Figure 138: Oceania Attractiveness by Route of Administration, 2023 to 2033
Figure 139: Oceania Attractiveness by Distribution Channel, 2023 to 2033
Figure 140: Oceania Attractiveness by Country, 2023 to 2033
Figure 141: MEA Value (US$ Million) by Drug Type, 2023 to 2033
Figure 142: MEA Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 143: MEA Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 144: MEA Value (US$ Million) by Country, 2023 to 2033
Figure 145: MEA Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 146: MEA Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 147: MEA Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 148: MEA Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 149: MEA Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 150: MEA Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 151: MEA Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 152: MEA Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 153: MEA Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 154: MEA Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 155: MEA Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 156: MEA Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 157: MEA Attractiveness by Drug Type, 2023 to 2033
Figure 158: MEA Attractiveness by Route of Administration, 2023 to 2033
Figure 159: MEA Attractiveness by Distribution Channel, 2023 to 2033
Figure 160: MEA Attractiveness by Country, 2023 to 2033
